Transport barriers in transscleral drug delivery for retinal diseases.
Transscleral delivery has emerged as an attractive method for treating retinal disorders because it offers localized delivery of drugs as a less invasive method compared to intravitreal administration. Numerous novel transscleral drug delivery systems ranging from microparticles to implants have been reported. However, transscleral delivery is currently not as clinically effective as intravitreal delivery in the treatment of retinal diseases. Transscleral drug delivery systems require drugs to permeate through several layers of ocular tissue (sclera, Bruch's membrane-choroid, retinal pigment epithelium) to reach the neuroretina. As a result, a steep drug concentration gradient from the sclera to the retina is established, and very low concentrations of drug are detected in the retina. This steep gradient is created by the barriers to transport that hinder drug molecules from successfully reaching the retina. A review of the literature reveals 3 types of barriers hindering transscleral drug delivery: static, dynamic and metabolic. While static barriers have been examined in detail, the literature on dynamic and metabolic barriers is lacking. These barriers must be investigated further to gain a more complete understanding of the transport barriers involved in transscleral drug delivery.
Kim
Stephanie H
SH
Department of Chemical and Biomolecular Engineering, University of Maryland, College Park, MD 20892-5766, USA. kimstep@mail.nih.gov
Lutz
Robert J
RJ
Wang
Nam Sun
NS
Robinson
Michael R
MR
D001692:Biological Transport; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D010599:Pharmacokinetics; D012164:Retinal Diseases / Q000188:drug therapy*; D012590:Sclera / Q000378:metabolism*
D004364:Pharmaceutical Preparations